Metabolic effect in LDLR KO mice treated with SC-560, BM-573, or a combination of both drugs
| . | Placebo . | SC-560 . | BM-573 . | SC+BM . |
|---|---|---|---|---|
| Weight, g | 30 ± 1 | 29 ± 1.4 | 31 ± 1.2 | 30.5 ± 1.1 |
| Triglycerides, mg/dL | 251 ± 25 | 276 ± 21 | 267 ± 30 | 275 ± 28 |
| Cholesterol, mg/dL | 1030 ± 45 | 958 ± 51 | 972 ± 48 | 989 ± 55 |
| TxB2, ng/mL | 70 ± 15 | 8 ± 1.3* | 44 ± 8† | 9 ± 1.5* |
| IPF2a-III, pg/mL | 346 ± 32 | 352 ± 35 | 365 ± 29 | 125 ± 30‡ |
| Platelet aggregation U46619, LT% | 81 ± 5 | 76 ± 4 | 9 ± 2* | 8 ± 2* |
| Platelet aggregation AA, LT% | 80 ± 6 | 10 ± 2* | 7 ± 2* | 8 ± 1.5 |
| . | Placebo . | SC-560 . | BM-573 . | SC+BM . |
|---|---|---|---|---|
| Weight, g | 30 ± 1 | 29 ± 1.4 | 31 ± 1.2 | 30.5 ± 1.1 |
| Triglycerides, mg/dL | 251 ± 25 | 276 ± 21 | 267 ± 30 | 275 ± 28 |
| Cholesterol, mg/dL | 1030 ± 45 | 958 ± 51 | 972 ± 48 | 989 ± 55 |
| TxB2, ng/mL | 70 ± 15 | 8 ± 1.3* | 44 ± 8† | 9 ± 1.5* |
| IPF2a-III, pg/mL | 346 ± 32 | 352 ± 35 | 365 ± 29 | 125 ± 30‡ |
| Platelet aggregation U46619, LT% | 81 ± 5 | 76 ± 4 | 9 ± 2* | 8 ± 2* |
| Platelet aggregation AA, LT% | 80 ± 6 | 10 ± 2* | 7 ± 2* | 8 ± 1.5 |
Body weight and levels of total plasma triglycerides, cholesterol, isoprostane iPF2a-III, and TxB2, and the platelet aggregation responses to U-46619 and AA were measured in mice after 12 weeks on high-fat diet receiving placebo or the different drugs. Results are expressed as mean ± SEM.
LT indicates light transmission; AA, arachidonic acid.
*P < .001 versus placebo.
P =.02 versus placebo.
P < .01 versus SC-560 and BM-573.